Poland· PL-100517565
Lynozyfic
A medicinal product containing linvoseltamabum, registered in Poland by Regeneron Ireland DAC.
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Linvoseltamabum
- Manufacturer
- Regeneron Ireland DAC
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linvoseltamabum in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLYNOZYFICRegeneron Pharmaceuticals, Inc.
- CzechiaLYNOZYFICRegeneron Ireland Designated Activity Company, Dublin
- SpainLYNOZYFIC 200 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRegeneron Ireland Designated Activity Company
- FinlandLYNOZYFICRegeneron Ireland Designated Activity Company (DAC)
- IrelandLYNOZYFIC 200 mg concentrate for solution for infusionRegeneron Ireland Designated Activity Company
- IcelandLynozyficRegeneron Ireland Designated Activity Company
- NetherlandsLYNOZYFIC 200 mg concentraat voor oplossing voor infusieRegeneron Ireland Designated Activity Company
- BelgiumLynozyfic 200 mgRegeneron Ireland Designated Activity Company (DAC)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lynozyfic
- Liechtenstein · Lynozyfic
- Norway · Lynozyfic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c5b1b411-b7a8-471c-abdd-f05f0d6c633c GET /v1/drugs/c5b1b411-b7a8-471c-abdd-f05f0d6c633c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "5 mg/2,5 ml",
"packaging": "Rpz ¦ EU/1/25/1917/001 ¦ 161785\n1 fiol. 2,5 ml",
"substance": "Linvoseltamabum 5 mg/2.5 ml",
"common_name": "Linvoseltamabum",
"pl_product_id": "100517565",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about linvoseltamabum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.